ProKidney

PROK43

Penny Stock

$2.390.00%$0.00

Penny Stock

PROK43

$2.39

0.00%$0.00

Penny Stock

Performance History

Key Stats
Open	$2.44
Prev. Close	$2.39
EPS	-0.60
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$1.81B
PE Ratio	-

	LOW	HIGH
Day Range	2.37	2.57
52 Week Range	1.12	6.36

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.60

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About ProKidney (PROK)

ProKidney Corp. (PROK) is a leading healthcare company specializing in kidney-related products and services. With a rich history and a strong presence in the market, PROK has established itself as a trusted name in the industry. The company's stock price has shown consistent growth over the years, reflecting the investor confidence in its performance. PROK stock has witnessed significant appreciation, making it an attractive choice for investors looking for long-term returns.

PROK stock has seen a positive trend in recent years, with its value showing an upward trajectory. The company's commitment to innovation and delivering high-quality healthcare solutions has played a crucial role in driving this growth. Its extensive range of kidney-related products and services has helped it establish a strong foothold in the industry. PROK's stock price history demonstrates its ability to generate value for shareholders, making it a compelling investment option.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Timothy A. Bertram D.V.M., Ph.D.
Headquarters: Winston-Salem
Employees: 87
Exchange: NASDAQ

Keep an eye on ProKidney

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of ProKidney (PROK)?

ProKidney (PROK) has a market capitalization of $1.81B. The average daily trading volume is 1.01M, indicating the stock's liquidity and investor engagement.

help

What is ProKidney's (PROK) price per share?

The current price per share for ProKidney (PROK) is $2.39. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for ProKidney (PROK)?

For ProKidney (PROK), the 52-week high is $6.36, which is 166.11% from the current price. The 52-week low is $1.12, the current price is 113.39% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is ProKidney (PROK) a growth stock?

ProKidney (PROK) has shown an average price growth of 0.41% over the past three years. It has received a score of 16 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ProKidney as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is ProKidney (PROK) stock price performance year to date (YTD)?

As of the latest data, ProKidney (PROK) has a year-to-date price change of 39.77%. Over the past month, the stock has experienced a price change of -0.42%. Over the last three months, the change has been -6.64%. Over the past six months, the figure is 74.45%.

help

Is ProKidney (PROK) a profitable company?

ProKidney (PROK) has a net income of -$35.47M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$151.52M. Furthermore, the EBITDA is -$149.44M.